Clinical trials: Best Disease
Graft Vs Host Disease, Graft-versus-host-disease
A Feasibility Study Using CLINIMACS® for Alpha/Beta T-Cell Depletion in Stem Cell Transplant
Patients in need of an allogeneic hematopoietic cell transplant (HCT) are at risk of developing graft-versus-host-disease (GVHD).
- Trial name
- NCT04337515
- Testing
- CliniMacs®
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Christopher Dvorak
Schizophrenia, Psychotic Disorders
Bergen Psychosis Project 2 - The Best Intro Study
In the Bergen Psychosis Project 2 the antipsychotic drugs aripiprazole, amisulpride, and olanzapine will be compared head-to-head in patients with schizophrenia and related psychoses and followed for 12 months.
- Trial name
- BP2 (NCT01446328)
- Testing
- Amisulpride, Aripiprazole, Olanzapine
- Where
- 4 sites in Austria, Norway
- Volunteers
- 151 people
- Sponsor
- Haukeland University Hospital
Prehabilitation, Pancreas Cancer
Preoperative Optimisation of Modifiable Risk Factors in Surgery of the Pancreas
The goal of this stepped-wedge randomized controlled trial is to investigate whether implementation of a best practice program for preoperative optimisation (prehabilitation program) with a focus on screening, assessment, and…
- Conditions
- Prehabilitation, Pancreas Cancer, Surgery, Postoperative Complications
- Trial name
- PROMISE-P (NCT05851534)
- Testing
- Preoperative optimisation program
- Where
- 13 sites in Netherlands
- Volunteers
- 2,575 people
- Sponsor
- Maastricht University Medical Center
Stomach Neoplasm, Neoplasm Metastasis
Irinotecan Versus Only Best Supportive Care for Gastric Cancer
The median survival at progression after first-line chemotherapy for metastatic gastric cancer is about 2.5 months. There are no data which a possible benefit of second line therapy.
- Trial name
- NCT00144378
- Testing
- Irinotecan
- Where
- Germany
- Volunteers
- 44 people
- Sponsor
- Charite University, Berlin, Germany
Acute Coronary Syndrome, Depressive Disorder
Comorbid Mental Disease and Heart Disease in Men
Mood disorders, anxiety disorders, and trauma-related stress (MD\AD\TRS) are common among men, particularly those suffering from heart disease (HD).
- Conditions
- Acute Coronary Syndrome, Depressive Disorder, Anxiety Disorders, Stress Disorders, Post-Traumatic
- Trial name
- MindTheHeart (NCT03354351)
- Testing
- Stepped-care model
- Volunteers
- 3,000 people
- Sponsor
- Universite de Moncton
Intermittent Claudication
An E-health Intervention for Patients With Peripheral Artery Disease
The specific study aim is to determine whether a 12-week digitally delivered behavior change intervention for patients with peripheral artery disease increases walking ability, reduces smoking, improves quality of life and…
- Trial name
- I-PAD (NCT05029739)
- Testing
- A PAD-specific smartphone application (e-intervention) developed for patients with Peripheral Artery Disease
- Where
- 5 sites in Sweden
- Volunteers
- 155 people
- Sponsor
- Sahlgrenska University Hospital
Thrombocytopenia
Effects of a Platelet Transfusion Best Practices Alert
This study is to determine the effectiveness of a computerized clinical decision support tool (Best Practice Alert - BPA) in reducing unnecessary platelet transfusions based on guidelines published by national transfusion…
- Trial name
- NCT04155775
- Testing
- Computer electronic health record alert (Best Practice Alert - BPA)
- Where
- United States
- Volunteers
- 446 people
- Sponsor
- Stanford University
Pain, Incontinence, Urinary
Sumamos Excelencia 2022
There is a gap between research and clinical practice, leading to variability in decision-making. Clinical audits are an effective strategy for improving implementation of best practices.
- Conditions
- Pain, Incontinence, Urinary, Obesity, Childhood, Breastfeeding
- Trial name
- NCT05466656
- Testing
- Continuous quality improvement cycle model
- Where
- Spain
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- Teresa Moreno Casbas
Advanced Systemic Mastocytosis, Aggressive Systemic Mastocytosis
Retrospective Study Assessing the Effect of Avapritinib Versus Best Available Therapy in Patients With AdvSM
BLU-285-2405 is a multi-center, synthetic control, observational and retrospective study designed to compare clinical outcomes for avapritinib compared with best available therapy for patients with AdvSM.
- Conditions
- Advanced Systemic Mastocytosis, Aggressive Systemic Mastocytosis, Systemic Mastocytosis With an Associated Hematological Neoplasm, Mast Cell Leukemia
- Trial name
- NCT04695431
- Where
- 6 sites in United States, Austria and 3 more
- Volunteers
- 317 people
- Sponsor
- Blueprint Medicines Corporation
Macular Edema
Efficacy and Safety of VEGF Trap Eye in Diabetic Macular Edema (DME) With Central Involvement
To determine the efficacy of intravitreally (IVT) administered VEGF Trap-Eye on the best-corrected visual acuity (BCVA) assessed by the early treatment diabetic retinopathy study (ETDRS) chart in subjects with diabetic macular…
- Trial name
- VIVID EAST (NCT01783886)
- Testing
- Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321), Macular Laser Photocoagulation
- Where
- 25 sites in China, Hong Kong and 2 more
- Volunteers
- 381 people
- Sponsor
- Bayer
Advanced Gastrointestinal Stromal Tumors
A Prospective, Multicenter Study on Best Clinical Use of Imatinib in the Advanced Gastrointestinal Stromal Tumors
Open-label, multicenter study of imatinib (400mg/die p.o.)in patients with advanced gastrointestinal stromal tumors. Patients will be treated for up to 12 months.
- Trial name
- NCT00940563
- Testing
- Imatinib
- Where
- 26 sites in Italy
- Volunteers
- 135 people
- Sponsor
- Novartis Pharmaceuticals
Hepatocellular Carcinoma
A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein
The purpose of this study is to evaluate the safety and efficacy of ramucirumab in participants with hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein.
- Trial name
- REACH-2 (NCT02435433)
- Testing
- Ramucirumab
- Where
- 131 sites in United States, Australia and 18 more
- Volunteers
- 399 people
- Sponsor
- Eli Lilly and Company
Liver Cancer
Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib Treatment
The purpose of this study is to determine if Brivanib is an effective treatment for liver cancer in patients who have failed or could not take Sorafenib
- Trial name
- BRISK PS (NCT00825955)
- Testing
- Brivanib, Best Supportive Care
- Where
- 113 sites in United States, Argentina and 17 more
- Volunteers
- 587 people
- Sponsor
- Bristol-Myers Squibb
Pancreatic Cancer Non-resectable
Stereotactic Radiotherapy vs Best Supportive Care in Unfit Pancreatic Cancer Patients
SUMMARY Rationale: Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers, its incidence increases with age. Many patients with localized (non-metastatic) PC have significant comorbidities, advanced age or a…
- Trial name
- PANCOSAR (NCT05265663)
- Testing
- stereotactic ablative radiotherapy
- Where
- 2 sites in Netherlands
- Volunteers
- 98 people
- Sponsor
- Amsterdam UMC, location VUmc
COVID-19
Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.
CALAVI will investigate the safety, efficacy and pharmacokinetics of acalabrutinib together with Best Supportive Care in the treatment of COVID-19.
- Trial name
- CALAVI (NCT04346199)
- Testing
- Acalabrutinib
- Where
- 50 sites in Argentina, Brazil and 12 more
- Volunteers
- 177 people
- Sponsor
- AstraZeneca
Postnatal Depression
Three Model Care Pathways for Postnatal Depression
The study evaluates three best-practice care pathways for postnatal depression (PND) by comparing sole General Practitioner (GP) management to GP management in combination with CBT-based counselling from either a Psychologist or…
- Trial name
- NCT01002027
- Testing
- CBT-Counselling
- Where
- Australia
- Volunteers
- 68 people
- Sponsor
- University of Melbourne
Psychotic Disorders
Cognitive Remediation and Supported Education in Psychotic Disorders
This trial aims to assess the added value of cognitive remediation therapy to supported education intervention in young adults with a psychotic disorder.
- Trial name
- REUSSIR (NCT04040829)
- Testing
- Cognitive remediation therapy (CR), Supported education (SE), Treatment as usual (TAU)
- Where
- 3 sites in Canada
- Volunteers
- 9 people
- Sponsor
- Centre de Recherche de l'Institut Universitaire en Santé Mentale de Québec
Shigellosis
A Study to Determine If a New Shigella Vaccine is Safe, Induces Immunity and The Best Dose Among Kenyan Infants
In this study, the tetravalent bioconjugate candidate vaccine Shigella4V will be tested to obtain first-in-human data on its safety and immunogenicity in infants and to identify the preferred dose of Shigella4V in 9 month old…
- Trial name
- NCT04056117
- Testing
- Shigella 4V, MenACWY, Rabies
- Where
- 2 sites in Kenya
- Volunteers
- 597 people, healthy volunteers welcome
- Sponsor
- LimmaTech Biologics AG
Myelodysplastic Syndrome
A Study Comparing Siltuximab Plus Best Supportive Care to Placebo Plus Best Supportive Care in Anemic Patients With International Prognostic Scoring System Low- or Intermediate-1-Risk Myelodysplastic Syndrome
The purpose of this study is to evaluate the efficacy of siltuximab, demonstrated by a reduction in red blood cell (RBC), transfusions to treat the anemia of Myelodysplastic Syndrome (MDS).
- Trial name
- NCT01513317
- Testing
- Siltuximab, Best supportive care (BSC)
- Where
- 23 sites in United States, Australia and 5 more
- Volunteers
- 76 people
- Sponsor
- Janssen Research & Development, LLC
Eating Disorder, Daily Activities
Efficacy of a Positive Psychological Intervention in Patients With Eating Disorders
This study is aimed to test the efficacy of a positive psychological intervention for promoting positive emotions and optimistic thinking in eating disordered patients.
- Trial name
- NCT03003910
- Testing
- Best Possible Self, Daily Activities
- Where
- Spain
- Volunteers
- 54 people
- Sponsor
- Universitat Jaume I